| Aug 12 |
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
|
| Aug 12 |
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
|
| Aug 12 |
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
|
| Aug 9 |
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
|
| Aug 8 |
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
|
| Aug 8 |
Citius wins FDA nod for Lymphir in cutaneous T-cell lymphoma
|
| Aug 8 |
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
| Aug 5 |
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
|
| Aug 5 |
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
|
| Jul 18 |
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
|
